Gilad Oren 4
4 · Aprea Therapeutics, Inc. · Filed Mar 28, 2024
Insider Transaction Report
Form 4
Gilad Oren
DirectorPresident/CEO
Transactions
- Award
Common Stock
2024-03-28+6,725→ 331,495 total - Award
Stock Options (Right to Buy)
2024-03-28+26,900→ 26,900 totalExercise: $6.69Exp: 2024-03-28→ Common Stock (26,900 underlying)
Holdings
- 600(indirect: By son)
Common Stock
- 1,200(indirect: By daughter)
Common Stock
Footnotes (3)
- [F1]These shares represent restricted stock units ("RSUs") and shall vest and be settled in the Issuer's common stock ("Common Stock") in three (3) equal annual installments beginning on March 28, 2025, until vested in full, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
- [F2]The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
- [F3]Twenty-five percent of these options vest on March 28, 2025, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.